The R-Pharm Group of Companies received approval from the Ministry of Health of the Republic of Turkey to conduct clinical trials of an original drug for the treatment of familial Mediterranean fever (goflikicept). The tests will be carried out in partnership with the Turkish company TRPharm.
Goflikicept is a groundbreaking protein medication that neutralizes the cytokine interleukin-1β (IL-1), a pivotal factor in the progression of Mediterranean fever.
The clinical trials will be conducted at five centers; patient recruitment is still ongoing. In addition to Turkey, it is planned to involve several other countries in the tests, including Armenia. In Russia, trials are carried out at the Clinic of Rheumatology, Nephrology and Occupational Pathology named after E.M. Tareev, Sechenov University, the Botkin Hospital named after S.P. Botkin and the the Saint-Petersburg Pasteur Institute. In total, the program plans to recruit 60 patients.
Familial Mediterranean fever (FMF) is an autoinflammatory genetic disorder that mainly affects people of Mediterranean origin. FMF is characterized by recurrent episodes of fever and serositis (chest, abdomen, joints), leading to painful attacks early during childhood. Amyloidosis is the most fatal complication of FMF
